Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-29 1:46 pm Purchase |
2025-06-30 | 13G | Jade Biosciences, Inc. JBIO |
The Vanguard Group | 1,807,582 5.600% |
1,807,582 (New Position) |
Filing History |
| 2025-07-17 8:12 pm Purchase |
2025-06-30 | 13G | Jade Biosciences, Inc. JBIO |
BlackRock Inc. BLK |
1,714,338 5.300% |
1,714,338 (New Position) |
Filing History |
| 2025-06-20 4:23 pm Purchase |
2025-04-28 | 13G | Jade Biosciences, Inc. JBIO |
Deep Track Capital, LP | 2,784,648 8.640% |
2,784,648 (New Position) |
Filing History |
| 2025-06-06 10:03 am Purchase |
2025-05-30 | 13G | Jade Biosciences, Inc. JBIO |
FMR LLC | 4,735,951 14.700% |
4,735,951 (New Position) |
Filing History |
| 2025-05-15 4:33 pm Purchase |
2025-04-28 | 13G | Jade Biosciences, Inc. JBIO |
TCG Crossover GP I, LLC | 64,023 0.200% |
64,023 (New Position) |
Filing History |
| 2025-05-05 4:26 pm Purchase |
2025-04-28 | 13G | Jade Biosciences, Inc. JBIO |
Venrock Healthcare Capital Partners III, L.P. | 3,220,369 9.900% |
3,220,369 (New Position) |
Filing History |
| 2025-05-05 09:43 am Purchase |
2025-04-28 | 13G | Jade Biosciences, Inc. JBIO |
Frazier Life Sciences Public Fund, L.P. | 1,772,116 5.500% |
1,772,116 (New Position) |
Filing History |
| 2025-05-01 6:31 pm Purchase |
2025-04-28 | 13D | Jade Biosciences, Inc. JBIO |
Fairmount Funds Management LLC | 7,249,356 19.990% |
7,249,356 (New Position) |
Filing History |
| 2025-04-30 4:51 pm Purchase |
2025-04-28 | 13D | Jade Biosciences, Inc. JBIO |
RA Capital Management, L.P. | 1,324,954 4.100% |
1,324,954 (New Position) |
Filing History |
| 2025-04-30 4:29 pm Purchase |
2025-04-28 | 13D | Jade Biosciences, Inc. JBIO |
Atlas Venture Fund XII, L.P. | 51,406 0.200% |
51,406 (New Position) |
Filing History |
| 2024-11-14 4:21 pm Sale |
2024-09-30 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 17,970 2.200% |
-30,045 (-62.57%) |
Filing History |
| 2024-06-20 6:00 pm Purchase |
2024-06-17 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 264,060 32.000% |
26,517 (+11.16%) |
Filing History |
| 2024-04-30 4:16 pm Purchase |
2024-04-26 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 237,542 28.900% |
595 (+0.25%) |
Filing History |
| 2024-02-20 7:09 pm Purchase |
2023-06-21 | 13D | Aerovate Therapeutics, Inc. AVTE |
Sofinnova Venture Partners X L.P. | 108,780 13.800% |
677 (+0.63%) |
Filing History |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Citadel Advisors LLC | 94 0.000% |
-44,534 (-99.79%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 48,015 6.100% |
-8,467 (-14.99%) |
Filing History |
| 2024-02-14 3:08 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 34,620 4.380% |
-21,298 (-38.09%) |
Filing History |
| 2024-02-09 4:28 pm Purchase |
2023-06-16 | 13G | Aerovate Therapeutics, Inc. AVTE |
TCG Crossover GP I, LLC | 62,894 8.000% |
62,894 (New Position) |
Filing History |
| 2023-06-27 5:00 pm Purchase |
2023-06-26 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 236,947 30.000% |
833 (+0.35%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 56,482 8.000% |
4,145 (+7.92%) |
Filing History |